Vepdegestrant Prolongs PFS in a Subgroup of Patients with ER-positive, HER2-negative Advanced Breast Cancer with ESR1 mutations By Ogkologos - June 30, 2025 692 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VERITAC-2 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR ESMO 2022: New Research in Treating Gastrointestinal and Genitourinary Cancers November 10, 2022 FDA Amends Indication for Pembrolizumab in the First-Line Treatment for Patients... November 30, 2023 Virtual Mind–Body Fitness Classes Show Unexpected Benefit in People with Cancer December 15, 2023 HTAN: Mapping Tumors across Space and Time Using Cutting-Edge Technologies February 12, 2019 Load more HOT NEWS Workout Wednesdays – Chest Exercises Part 1 McDonald’s Customer Buys Breakfast For Mom And Soldier Son, Unaware Of... Remodeled CAR T-Cell Therapy Reduces Side Effects in First Clinical Trial Mom Thinks Baby Died Until Firefighters Say The Family Dog Made...
